RVL Pharmaceuticals PLCOver The Counter Market:RVLPQ
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RVLPQ |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RVL Pharmaceuticals PLC | 110.0 | 0.0x | --- |
Centogene NV | 2.8M | -0.1x | --- |
Molecular Templates Inc | 2.5M | -0.1x | --- |
Precision BioSciences Inc | 49.9M | 8.5x | --- |
Pieris Pharmaceuticals Inc | 21.0M | -1.3x | --- |
Champions Oncology Inc | 58.0M | -16.8x | --- |
Company Information
RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.
Contact Information
- Headquarters
- 400 CROSSING BOULEVARDBRIDGEWATER, NJ, United States 08807
- Phone
- 908-809-1300
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer, Chief Financial Officer
- Brian Markison
- Chief Operating Officer, Executive Vice President
- James Schaub
- General Counsel, Secretary
- Christopher Klein
- Non-Executive Independent Director
- Gregory Cowan
- Non-Executive Independent Director
- Michael Debiasi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $110.00 |
|---|---|
Revenue (TTM) | $36.9M |
Shares Outstanding | 111.4M |
RVL Pharmaceuticals PLC does not pay a dividend. | |
Beta | --- |
EPS | $-0.70 |
Book Value | $0.52 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -191.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
